AAPS PharmSciTech

, Volume 7, Issue 3, pp E1–E11 | Cite as

Osmotic flow through asymmetric membrane: A means for controlled delivery of drugs with varying solubility

  • Anil K. Philip
  • Kamla Pathak


A nondisintegrating, controlled release, asymmetric membrane capsular system of flurbiprofen was developed and evaluated for controlled release of the drug to overcome some of its side effects. Asymmetric membrane capsules were prepared using fabricated glass mold pins by phase inversion process. The effect of different formulation variables was studied based on 23 factorial design; namely, level of osmogen, membrane thickness, and level of pore former. Effects of polymer diffusibility and varying osmotic pressure on drug release were also studied. Membrane characterization by scanning electron microscopy showed an outer dense region with less pores and an inner porous region for the prepared asymmetric membrane. Differential scanning calorimetry studies showed no incompatibility between the drug and the excipients used in the study. In vitro release studies for all the prepared formulations were done (n=6). Statistical test (Dunnett multiple comparison test) was applied for in vitro drug release atP>.05. The best formulation closely corresponded to the extra design checkpoint formulation by a similarity (f2) value of 92.94. The drug release was independent of pH but dependent on the osmotic pressure of the dissolution medium. The release kinetics followed the Higuchi model and the mechanism of release was Fickian diffusion.


asymmetric membrane factorial design extra design polymer diffusibility 


  1. 1.
    Santus G, Baker RW. Osmotic drug delivery: a review of the patent literature.J Control Release. 1995;35:1–21.CrossRefGoogle Scholar
  2. 2.
    Theeuwes F. Elementary osmotic pump.J Pharm Sci. 1975;64: 1987–1991.CrossRefPubMedGoogle Scholar
  3. 3.
    Theeuwes F, Saunders RJ, Mefford WS, inventors. Process for forming outlet passageways in pills using a laser. US parent 4 088 864. May 9, 1978.Google Scholar
  4. 4.
    Herbig SM, Cardinal JR, Korsmeyer RW, Smith KL. Asymmetric membrane tablet coatings for osmotic drug delivery.J Control Release. 1995;35:127–136.CrossRefGoogle Scholar
  5. 5.
    Thombre AG, Cardinal JR, DeNoto AR, Gibbes DC. Asymmetric membrane capsules for osmotic drug delivery. II. In vitro and in vivo drug release performance.J Control Release. 1999;57:65–73.CrossRefPubMedGoogle Scholar
  6. 6.
    Thombre AG, Cardinal JR, DeNoto AR, Herbig SM, Smith KL. Asymmetric membrane capsules for osmotic drug delivery. I. Development of a manufacturing process.J Control Release. 1999;57:55–64.CrossRefPubMedGoogle Scholar
  7. 7.
    Lin YK, Ho HO. Investigations on the drug releasing mechanism from an asymmetric membrane-coated capsule with an in situ formed delivery orifice.J Control Release. 2003;89:57–69.CrossRefPubMedGoogle Scholar
  8. 8.
    Marsh CC, Schuna AA, Sundstorm WR. A review of selected investigational nonsteroidal antiinflammatory drugs of the 1980s.Pharmacotherapy. 1986;6:10–25.CrossRefPubMedGoogle Scholar
  9. 9.
    Gilman AG, Rall TW, Taylor P.Goodman and Gillman’s The Pharmacological Basis of Therapeutics. New York, NY: Pergamon Press; 1990.Google Scholar
  10. 10.
    British Medical Association and Royal Pharmaceutical Society of Great Britain.British National Formulary 45. London, UK: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2003.Google Scholar
  11. 11.
    Thaller VT, Kulshrestha MK, Bell K. The effect of pre-operative topical flurbiprofen or diclofenac on pupil dilatation.Eye. 2000; 14:642–645.CrossRefPubMedGoogle Scholar
  12. 12.
    Chandran C, Roy A, Saha RN. Flurbiprofen: a review.Indian J Pharm Educ. 2005;39:22–26.Google Scholar
  13. 13.
    McClelland GA, Sutton SC, Engle K, Zentner GM. Solubility modulated osmotic pump: in vitro/in vivo release of diltiazem hydrochloride.Pharm Res. 1991;8:88–92.CrossRefPubMedGoogle Scholar
  14. 14.
    Zentner GM, McClelland GA, Sutton SC. Controlled porosity solubility and resin modulated osmotic drug delivery systems for release of diltiazem hydrochloride.J Control Release. 1991;16:237–244.CrossRefGoogle Scholar
  15. 15.
    Martin A.Physical Pharmacy. New Delhi, India, B. I. Waverly Pvt Ltd; 1999.Google Scholar
  16. 16.
    Rawlins EA.Bentley’s Textbook of Pharmaceutics. London, UK: Bailliere Tindall 2004.Google Scholar
  17. 17.
    Bennett PN, Brown MJ.Clinical Pharmacology. London, UK: Churchill Livingstone; 2004.Google Scholar
  18. 18.
    Chien YW.Novel Drug Delivery Systems. New York NY: Marcel Dekker Inc; 1992.Google Scholar
  19. 19.
    Najib N, Suleiman M. The kinetics of drug release from ethyl cellulose solid dispersions.Drug Dev Ind Pharm. 1985;11: 2169–2181.CrossRefGoogle Scholar
  20. 20.
    Desai SJ, Singh P, Simonelli AP, Higuchi WI. Investigation of factors influencing release of solid drug dispersed in wax matrices. III. Quantitative studies involving polyethylene plastic matrix.J Pharm Sci. 1966;55:1230–1234.CrossRefPubMedGoogle Scholar
  21. 21.
    Higuchi T. Mechanism of sustained action medication, theoretical analysis of rate of release of solid drugs dispersed in solid matrices.J Pharm Sci. 1963;52:1145–1149.CrossRefPubMedGoogle Scholar
  22. 22.
    Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation: I—theoretical consideration.Ind Eng Chem. 1931;23:923–931.CrossRefGoogle Scholar
  23. 23.
    Korsmeyer RW, Gurny R, Doelker EM, Buri P, Peppas NA. Mechanism of solute release from porous hydrophilic polymers.Int J Pharm. 1983;15:25–35.CrossRefGoogle Scholar
  24. 24.
    Avdeef A. pH-metric solubility 1: solubility pH profiles from bjerrum plots. Gibbs buffer and pKa in solid state.Pharmacy and Pharmacology Communications. 1998;4:165–178.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2006

Authors and Affiliations

  1. 1.Department of PharmaceuticsRajiv Academy for PharmacyMathuraUttar PradeshIndia

Personalised recommendations